- Home
- ASMB vs SFWL Comparison
ASMB vs SFWL Comparison
Compare ASMB & SFWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASMB
- SFWL
- Stock Information
- Founded
- ASMB 2005
- SFWL 2001
- Country
- ASMB United States
- SFWL China
- Employees
- ASMB N/A
- SFWL N/A
- Industry
- ASMB Biotechnology: Pharmaceutical Preparations
- SFWL Trucking Freight/Courier Services
- Sector
- ASMB Health Care
- SFWL Industrials
- Exchange
- ASMB Nasdaq
- SFWL Nasdaq
- Market Cap
- ASMB 139.8M
- SFWL 81.0M
- IPO Year
- ASMB 2010
- SFWL 2023
- Fundamental
- Price
- ASMB $18.75
- SFWL $1.00
- Analyst Decision
- ASMB Strong Buy
- SFWL
- Analyst Count
- ASMB 3
- SFWL 0
- Target Price
- ASMB $33.00
- SFWL N/A
- AVG Volume (30 Days)
- ASMB 43.5K
- SFWL 10.8K
- Earning Date
- ASMB 08-07-2025
- SFWL 09-04-2025
- Dividend Yield
- ASMB N/A
- SFWL N/A
- EPS Growth
- ASMB N/A
- SFWL 4.79
- EPS
- ASMB N/A
- SFWL 0.13
- Revenue
- ASMB $32,154,000.00
- SFWL $504,158,000.00
- Revenue This Year
- ASMB $0.04
- SFWL N/A
- Revenue Next Year
- ASMB N/A
- SFWL N/A
- P/E Ratio
- ASMB N/A
- SFWL $7.65
- Revenue Growth
- ASMB 148.33
- SFWL 24.75
- 52 Week Low
- ASMB $7.75
- SFWL $0.86
- 52 Week High
- ASMB $19.93
- SFWL $1.60
- Technical
- Relative Strength Index (RSI)
- ASMB 65.84
- SFWL 54.48
- Support Level
- ASMB $18.01
- SFWL $0.96
- Resistance Level
- ASMB $18.99
- SFWL $1.02
- Average True Range (ATR)
- ASMB 0.84
- SFWL 0.05
- MACD
- ASMB -0.05
- SFWL 0.00
- Stochastic Oscillator
- ASMB 84.42
- SFWL 90.91
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
About SFWL Shengfeng Development Limited
Shengfeng Development Ltd is a holding company. Through its subsidiaries, it offers contract logistics services in China. The contract logistics services offered by the company include planning and designing supply chains, designing facilities, processing orders, collecting payments, managing inventories, and providing client services.